Micron Biomedical: A Shot of Innovation Without the Needle

ALPHARETTA, Ga. – March 30, 2026 – A future where life-saving vaccines and medicines are administered without a single needle is moving closer to reality, thanks to the pioneering work of Micron Biomedical. The Georgia-based company has just been named to the number two spot on Fast Company’s prestigious 2026 list of the World’s Most Innovative Companies in the "smaller companies" category, a significant acknowledgment of its potential to reshape global health.

The recognition celebrates Micron Biomedical's development of a dissolvable, needle-free technology designed to replace traditional injections. This innovation addresses some of the most persistent bottlenecks in medicine, from patient anxiety to complex logistical hurdles, positioning the clinical-stage company as a leader in a new era of drug delivery.

The End of the Needle?

For millions of people, the fear of needles—or trypanophobia—is a significant barrier to receiving essential medical care. Beyond patient anxiety, the reliance on injections creates a cascade of challenges for healthcare systems worldwide. As Fast Company noted in its recognition, "Having no access to care can keep patients from getting the injections they need. Rural areas, clinician shortages, and challenges with expiration all add barriers to getting sometimes life-saving care."

Micron Biomedical is tackling these problems head-on with its unique needle-free technology. The company has developed a "therapeutic button"—a dissolvable microarray compound that is pressed painlessly onto the skin. Thousands of microscopic projections, no taller than the width of a human hair, penetrate only the uppermost layers of skin, rapidly delivering the vaccine or therapeutic before dissolving harmlessly. The process is designed to be simple enough for self-administration or for use by a caregiver with minimal training.

This approach not only eliminates the pain and fear associated with injections but also produces no medical sharps waste, a significant environmental and safety benefit. Furthermore, the technology’s design offers inherent thermostability, reducing or even eliminating the need for the cumbersome and costly "cold chain" of refrigeration required to transport and store many of today's injectable medicines.

“Removing the most significant bottlenecks in how vaccines and medicines are manufactured, distributed and administered requires not only transformative, cost-efficient solutions, but also strong public confidence in those approaches,” said Steven Damon, CEO of Micron Biomedical. “As a Fast Company Most Innovative Company, we are honored that our dissolvable therapeutic button technology continues to be recognized for aligning with patient preferences while delivering clinical effectiveness.”

A Game Changer for Global Health Equity

The implications of this technology extend far beyond convenience in developed nations. For global health initiatives, it represents a potential quantum leap forward. The VIPS Alliance—a consortium of the world's leading health organizations including the World Health Organization, GAVI, UNICEF, PATH, and the Bill & Melinda Gates Foundation—has heralded this class of technology as the highest global priority for overcoming immunization barriers in low- and middle-income countries.

These organizations recognize that simplifying delivery is key to boosting vaccination rates and fighting infectious diseases. Micron’s patches can be easily and cost-effectively transported to remote villages, stored without reliable electricity, and administered by local health workers, parents, or even individuals themselves.

This potential has attracted substantial support. The Bill & Melinda Gates Foundation has provided a $23.6 million grant to help Micron Biomedical scale up mass production of its needle-free measles-rubella (MR) vaccine, along with an additional $7.5 million for a Phase 2 clinical trial. Similarly, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded the company $3.7 million to advance research into needle-free vaccines against "Disease X," a term for unknown future pandemic threats, underscoring the technology's role in future pandemic preparedness.

Validated Science in a Competitive Field

While the vision is compelling, Micron Biomedical is backing it with rigorous scientific validation. The company has already published positive Phase 1/2 clinical data for its MR vaccine patch in The Lancet, demonstrating a robust and safe immune response in children as young as nine months old that was comparable to traditional injections.

The company is also a key partner in the first-ever CDC-sponsored clinical trial of a vaccine delivered via patch technology, focusing on a novel rotavirus vaccine. Previous clinical data for a seasonal influenza vaccine patch also showed a strong immune response, with participants overwhelmingly preferring the needle-free method. Studies are underway for other applications, including contraception, diabetes management, and weight loss drugs.

Micron Biomedical is not alone in the needle-free space. It faces competition from companies like Vaxxas, with its High Density Microarray Patch, and PharmaJet, which specializes in jet injectors. However, Micron's focus on a dissolvable microarray, combined with its demonstrated thermostability and ease of use, provides a powerful set of differentiators in a market ripe for disruption.

Scaling Up for a Global Market

The Fast Company award comes at a time of significant growth for Micron Biomedical. The company recently celebrated major scientific and financial milestones, including the opening of a new 26,000-square-foot hub for development and at-scale manufacturing. To achieve the massive production volumes needed for global health campaigns, Micron has forged a strategic partnership with LTS Lohmann, a leading pharmaceutical contract manufacturer, to build out a GMP-compliant automated production line.

This expansion is fueled by a successful Series A financing round that has grown to over $33 million, with key investments from J2 Ventures and the Global Health Investment Corporation. The capital is being deployed to accelerate the path to commercialization for its pipeline of needle-free therapeutics and vaccines.

“Our list of the Most Innovative Companies is about spotlighting organizations that don’t just adapt to change—they drive it,” said Brendan Vaughan, editor-in-chief of Fast Company. “The companies we honor this year are redefining what leadership looks like in 2026, pairing bold ideas with measurable impact and turning breakthrough innovation into real-world value.”

For Micron Biomedical, that real-world value lies in the promise of a healthier, more equitable world where access to medicine is no longer limited by the sharp end of a needle. With additional data expected to be presented at the 2026 World Vaccine Congress in Washington, D.C., later this month, the industry and the world will be watching closely.